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ABSTRACT
Background. Early discontinuation of aromatase inhibitors
(AIs) is common and leads to poor outcomes but is challenging
topredict. In the Exemestane and Letrozole Pharmacogenetics
trial, ahigh rateofearlydiscontinuationdue to intolerancewas
observed. We hypothesized that early changes in patient-
reported outcomes (PROs) predict AI discontinuation and that
biochemical factors are associated with changes in PROs.
Patients and Methods. Postmenopausal women with early-
stage breast cancer enrolled in a prospective randomized trial
of exemestane versus letrozole completed questionnaires at
baseline and serially over 24months to assess overall quality of
life (EuroQOL Visual Analog Scale [VAS]); mood; and multiple
symptoms, includingamusculoskeletal symptomcluster. A joint
mixed-effects/survivalmodelwas used toestimate the effect of
thechange inPROsonAIdiscontinuation.Associationsbetween
biochemical factors and change in PROs were examined.
Results. A total of 490 patients were analyzed. Worsening of
EuroQOL VAS and the musculoskeletal cluster were associated
with the highest risk for early discontinuation (hazard ratio [HR],
2.77 [95%confidence interval (CI), 2.72–2.81;p5 .015]; HR, 4.39
[95% CI, 2.40–8.02; p, .0001], respectively). Pharmacokinetics
and estrogen metabolism were not consistently associated with
change in PRO measures. No clinically significant differences in
any PRO between AIs were observed.
Conclusion. Changes in PROs early during AI therapy were
associatedwith treatmentdiscontinuation. Identificationof these
changes could be used to target interventions in patients at high
risk for early discontinuation.The Oncologist 2016;21:539–546
Implications for Practice: Early changes in patient-reported outcomes (PROs) can predict nonpersistence to aromatase inhibitor
therapy. If used in clinical practice, PROsmight identifywomen at highest risk for early discontinuation and allow for interventions
to improve tolerancebefore significant toxicities develop. Further research is needed to improve capturing PROs in routine clinical
practice.
INTRODUCTION
Aromatase inhibitors (AIs) improve survival compared with
tamoxifen and are the preferred adjuvant therapy for post-
menopausal women with hormone receptor-positive breast
cancer [1]. Previous large adjuvant endocrine trials have
reported no significant decrease in overall health-related
quality of life (HRQOL) during adjuvant AI therapy [2–4].
Despite these data, in multiple research and clinical practice
settings early discontinuation is common, ranging from 30%
to 70% [5]. Although reasons for early discontinuation are
multifactorial, data suggest that up to 30% of patients
discontinue AI therapy because of adverse symptoms, most
commonly arthralgias [6, 7].
Multiple studies have explored predictors of early
discontinuation on the basis of baseline demographic and/or
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clinicopathologic features; however, inconsistent results be-
tween studies havemade it difficult for clinicians to accurately
predict which patients are at greatest risk for early discontin-
uation. Interestingly, one report found that although a baseline
history of anxiety or depression was not associated with early
discontinuation, treatment for anxiety that developed after
initiation of endocrine therapy was associated with early
discontinuation [8]. This latter observation suggests that a
change in symptomburdenearly in thecourseof therapycould
be a predictor for discontinuation and that early identification
could possibly allow for earlier intervention.
TheExemestaneandLetrozolePharmacogenetics (ELPh) trial
was a randomized study to investigate the pharmacogenetic
influences on the effects of AI therapy; it included prospective
patient-reported outcome (PRO) measures throughout the
initial 24-months of AI therapy. Measures included were for
global HRQOL, depression, anxiety, and symptom burden. We
previously reporteda statistically significantdifference in time to
treatment discontinuation in this cohort, with a shorter time to
discontinuation for those treated with exemestane compared
with letrozole [6]. The primary objective of this exploratory
analysis was to determine whether early changes in PRO
measures predicted early discontinuation and compare
longitudinal changes in PROs by two distinct AIs. To examine
the mechanism underlying development of PROs during AI
therapy,wealsoexamined theassociationbetweenchanges in
PROs and various biochemical factors.On thebasis of previous
data [9], hypotheses were as follows: (a) there would be no
significant difference in PRO measures between AIs, (b)
negative early changes in PROs would predict early discontin-
uation, and (c) greater suppression of estrogen metabolites
would be associated with greater negative changes in PROs.
MATERIALS AND METHODS
Study Participants
Postmenopausal women with stage 0–III hormone receptor-
positive breast cancer who were initiating treatment with an AI
were eligible for enrollment on the ELPh trial. Details of the trial
havebeenpreviouslypublished (ClinicalTrials.govNCT00228956)
[6, 10]. In brief, all indicated surgery, chemotherapy, and/or
radiation therapy were completed before enrollment. Prior
tamoxifen therapy was permitted. No patients could have
previously received AI therapy for any reason. Supportive care
asdirectedby theclinical teamwaspermittedformanagement
of any treatment-emergent toxicity and was not protocol
driven except for offering patients the option to cross over to
the alternative AI. The institutional review boards at all three
participating sites (Johns Hopkins University, Indiana Univer-
sity,UniversityofMichigan) approved theclinical trial. Patients
were required to provide written informed consent before
undergoing study-related procedures.
Study Procedures
Patientswere randomlyassigned ina1:1 ratio to treatmentwith
exemestane (Aromasin; Pfizer, NewYork,NY), 25mgorally daily,
or letrozole (Femara;Novartis, Basel, Switzerland), 2.5mgorally
daily.Randomizationwasstratifiedbypriorchemotherapy,prior
tamoxifen, and bisphosphonate use. At baseline and after 1, 3,
6, 12, and 24 months, patients were clinically evaluated and
completedPROquestionnaires (seenextsection).Bloodsamples
were collected at baseline and after 3 months of therapy for
evaluation of estrogen metabolites and pharmacokinetics (PK).
PRO Questionnaires
Validated tools for HRQOL, depression, anxiety, and symptom
burden were used. Specifically, HRQOL was assessed by using
the EuroQOLVisual Analog Scale (VAS).The EuroQOLVAS is one
component of the EQ-5D; this 20-cm, Cantril-like ladder scale
ranging from 0 (death) to 100 (best health) has demonstrated
reliability and validity in populations with cancer [11]. The
minimally important difference for the EuroQOL VAS is 7–12
[12].DepressionwasassessedwiththeCenterforEpidemiologic
Studies–Depression (CESD) tool, a 20-item self-report tool that
evaluates for the presence and severity of depressive symp-
toms. Scores range from 0 to 60, with scores of 16 or higher
indicatinghighdepressivesymptoms [13].Anxietywasassessed
withtheanxietysubscaleoftheHospitalAnxietyandDepression
Scale (HADSA).This is a brief 7-item tool, and scores range from
0to21; scoresof8orhigher indicateanxiety [14].A47-itemtool,
composed largely of items from the Breast Cancer Prevention
Trial Symptom Checklist (BCPT-SCL) [15], assessed general
symptomburden (supplemental onlineTable1). Scores foreach
item range from 0 to 4, with a higher score indicating worse
symptomburden.Of the 47 items assessed, the current analysis
of general symptom burden used 34 items analyzed as six
separate symptom clusters (weight/body image, vasomotor,
vulvovaginal,musculoskeletal, cognitive, andmood) developed
by using methods described later in the text.
Laboratory Studies
Aspreviouslydescribed,serumsamplesobtainedatbaselineandat
3 months were assayed for estradiol (E2), estrone-1-sulfate (E1S),
and estrone (E1) by using an ultrasensitive gas chromatography/
tandem mass spectroscopy assay [16]. The lower limits of
quantification were 0.625 pg/mL for E2, 2.88 pg/mL for E1S,
and 1.56 pg/mL for E1. Serum concentrations of exemestane
and letrozole were measured at baseline and follow-up at
3 months (Z. Desta, personal communication) [17].
Statistical Analysis
In this exploratory analysis, the first objective was to compare
earlychangesinPROmeanscoresfrombaselinetomonths1,3,and
6 among patients who continued therapy through 24 months
(persistent group) compared with those who discontinued
before 24months (nonpersistent) by using theWilcoxon rank-
sum test. In addition, we also analyzed whether the PRO
measures predicted for time to discontinuation, where discon-
tinuationof theinitialAI therapybefore24monthswasduetothe
developmentof intolerable toxicity (as reportedby thepatientas
the primary cause of treatment discontinuation). To account for
nonrandom dropout, a joint mixed-effects/survival model was
used toestimate theeffectof thechange inPROsover24months
on AI discontinuation. All PROs were modeled as continuous
variables.Natural cubic splineswereused inmodeling time forall
models with two to four knots (polynomial in time to allow for
nonlinearity of association between time and PRO).
For the symptom clusters, we ran a confirmatory factor
analysis at baseline to confirm the grouping of items based on
the BCPT-SCL eight-symptom scale [18] and found high levels of
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goodness of fit for all clusters except the vulvovaginal cluster.
Specifically, for the five other symptom clusters, the root mean
square error of approximationwas 0.043 (acceptablemodels use
,0.06) and the comparative fit index was 0.93 (acceptable,
.0.90). Foreachsymptomcluster, theoutcome is the square root
(fordistributionalpurposes inourmixedmodels)of thesumofthe
questions ineachclusterandtheaveragescorepercluster foreach
timepoint. Ifawomandidnotanswereveryquestioninthecluster,
we used the average of those questions that she did answer.
For the second objective, we analyzed the changes from
baseline in HRQOL, psychological distress, and symptom burden
during the 24-month study period between AIs. PRO evaluation
was missing at any time point after the patient had discontinued
the AI.Mean change scores frombaseline to each follow-up time
point for those who had not yet discontinued were compared
between treatment groups for all PRO domains and analyzed by
usingtheWilcoxonrank-sumtest.Anegativemeanchange inPRO
indicates the score decreased from baseline and a positive mean
change in PRO indicates the score increased from baseline.
Associationsbetweenbaselinevariablesof interest, includingage,
race, body mass index (BMI), prior use of tamoxifen, prior use of
chemotherapy(yesvs.noandtaxanevs.notaxane)andchanges in
PROswereassessedbyusingSpearmancorrelationforcontinuous
variables andWilcoxon rank-sum test for categorical variables.
Estrogen levels were measured at baseline and 3 months
by using estrone sulfate, estradiol, and estrone. The correla-
tions between the absolute estrogen level at 3months and the
change in estrogen frombaseline to 3monthswith the change
in EuroQOL VAS, CESD, HADSA, and symptom clusters were
examinedbyusing Spearmancorrelation.Onlyonemeasureof
PK datawas available (taken at 3months), so the drug PK level
at 3monthswas correlated to the change in PRO frombaseline
to 3 months using Spearman correlation. Multiple compari-
sonswerenot controlled for becauseof the exploratory nature
of the analysis. Statistical analyses were conducted using SAS
v9.3 (SAS Institute, Inc, Cary, NC, http://www.sas.com).
RESULTS
Patient Characteristics
Five hundred three patients signed informed consent. Three
patients withdrew from study participation before randomi-
zation (Fig. 1). Of the 500 eligible patients, 252 (50.4%) were
randomly assigned to letrozole and 248 (49.6%) to exemes-
tane. Ten patients (4%) were not included in the current
analysis: 5 in each treatment arm because of no time on drug
(n5 7), premenopausal status (n5 2), and no completed PRO
data (n51). Baseline characteristics for the490patients in the
current analysis are listed in Table 1.Most patientswerewhite
(n 5 434 [88%]), nearly half had received adjuvant chemo-
therapy (n5 222 [45%]), and 178 (36%) had been treatedwith
tamoxifen. Baseline scores for all PROs were not significantly
different between treatment arms, as shown in supplemental
online Table 2.
Longitudinal Effects of AI Therapy on PROs
Mean change by drug from baseline to each time point for
EuroQOL VAS, CESD, and HADSA are shown in supplemental
online Figure 1A–1C, respectively. Although statistically
significant differences between AIs were observed in mean
change frombaseline on the EuroQOLVASat 6months (23.27
for exemestane vs.20.38 for letrozole; p5 .03) and CESD at
3months (1.28 forexemestane vs.20.14 for letrozole;p5 .01),
these were isolated findings and not consistent over time or
symptom domain. No other significant differences in mean
changes from baseline to any time point during the 24-month
study period were found between treatment arms for these
measures. Mean change from baseline to each time point for
the six symptom clusters are shown in supplemental online
Table 3. Significant differences between drugs were found in
the weight/body image, musculoskeletal, and cognitive
symptom clusters; however, the differences were uncom-
monly and inconsistently observed during the study period.
Changes in PRO and AI Early Discontinuation
Ofthe490patientsanalyzed,156(32%)patientsdiscontinuedAI
treatment before 24 months because of toxicity. Of those, 88
(36.2%) randomly assigned to exemestane and 68 (27.5%)
randomlyassignedto letrozolediscontinuedtherapy (p5 .039).
Forty-seven additional patients discontinued for reasons other
than toxicity, such as recurrence, nonadherence with study
procedures,andovarian functionrecovery.Earlychanges inPRO
mean scores (EuroQOLVAS, CESD, HADSA, andmusculoskeletal
[MSK] symptom cluster) from baseline tomonths 1, 3, and 6 by
thosewhocontinuedtherapyuntil24months(persistentgroup)
compared with those who discontinued before 24 months
(nonpersistent) are shown in Figure 2A–2D.Women who were
nonpersistentweremore likely tohaveworseEuroQOLVASand
MSK symptom cluster scores at all early time points compared
with those thatwere persistent. No early differences in CESD or
HADSA were observed.
Table 2 demonstrates the findings of the joint mixed-
effectsmodel used to estimate the effect of change in PROs on
early discontinuation of AIs. Worsening in EuroQOL VAS was
associatedwith increasedrisk forearlydiscontinuation (hazard
ratio [HR], 2.77; 95% confidence interval [CI], 2.72–2.81; p5
.015). Worsening in depression (CESD) and anxiety (HADSA)
scores was weakly associated with early discontinuation (HR,
1.04 [95%CI, 1.01–1.06;p5 .001] and1.04 [95%CI, 1.01–1.06;
p 5 .006], respectively). Worsening in the musculoskeletal,
cognitive, mood, and weight/body image clusters was also
associated with increased risk for early discontinuation. Of
these, the musculoskeletal symptom cluster was most highly
associated with increased risk for early discontinuation (HR,
4.39; 95% CI, 2.4–8.02; p, .0001).
Predictors of Changes in PROs During AI Therapy
Prior use of tamoxifen was not associated with any significant
difference inEuroQOLVAS,CESD,orHADSAthroughout thestudy
periodexceptEuroQOLVASat3months (23.1 forprior tamoxifen
vs.20.54fornotamoxifen;p5 .032)(datanotshown).Compared
with no prior tamoxifen use, prior tamoxifen use was associated
with greater worsening in the musculoskeletal symptom cluster,
lesser worsening at 3 months in the mood symptom cluster, and
lesser worsening in the vasomotor symptom cluster throughout
the study period. Prior exposure to chemotherapy or taxane
compared with no such exposure was associated with a lesser
worsening in the vasomotor symptom cluster and a greater
worsening inthevulvovaginalsymptomcluster(datanotshown).
Neither prior chemotherapynor taxaneexposurewas associated
www.TheOncologist.com ©AlphaMed Press 2016
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with a significant change in EuroQOL VAS, CESD, or HADSA. No
difference in themusculoskeletal symptomclusterwas observed
in patients with prior taxane exposure. No statistically significant
associations were identified between change in any PRO
measure during the 24-month study period and race, age, or
BMI (data not shown).
EffectofEstrogenMetabolismandAIPharmacokinetics
on PROs
We examined correlations between change in PROs and
change in both serum estrogen metabolite concentrations
(estradiol, estrone, estrogen sulfate) and AI concentration.
No clinically relevant associations were found (supplemental
online Table 4).
DISCUSSION
Comparedwith tamoxifen, upfront or sequential therapywith
an AI is associated with improved disease-free and overall
survival in postmenopausal women with hormone receptor-
positivebreastcancer [1, 19]. In theELPhclinical trial, one third
ofpatientsdiscontinuedAItreatmentbecauseofpatient-reported
intolerable symptom burden. We were able to identify early
changes in PROs in the cohort that ultimately stopped as a
result of treatment toxicity.These findings are consistent with
a recent retrospective cohort study that found joint pain
predicted for early AI discontinuation [20]. The ability to
identify patientswith high likelihood ofdeveloping intolerable
adverse effects could have clinical implications for proactive
symptom management strategies to minimize early discon-
tinuation and improve adherence to life-prolonging therapies.
Ina featureuniquetothisanalysis,wealsoexploredbiochemical
changes and demographic variables that affected changes in
PROmeasures and could provide amechanistic explanation for
the development of the changes; however, none showed a
consistent effect.
One challenge of studies of change in PROs during
therapy is missing data associated with early treatment
discontinuation. This is particularly true with AI therapy, for
whichahigh rateofearlydiscontinuationwith therapydue to
toxicity has been reported [6]. Bias can occur when women
with thegreatest symptomburdendiscontinue therapyearly
and do not contribute to the longitudinal PRO analyses. In
the current study, most of the 32% who discontinued did so
because of adverse symptoms at a median time of 6.1 months
Figure 1. Consolidated Standards of Reporting Trials diagram.
Abbreviation: PRO, patient-reported outcome.
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and therefore failed to contribute to the subsequent PRO
analyses.
Although we observed a greater worsening in EuroQOL VAS
and musculoskeletal symptom burden early in the treatment
course(baselinetomonths1,3,and6) inthosewhosubsequently
discontinued therapy compared with those who remained on
therapy, nonrandom dropout and multiple comparisons limit
these analyses. We attempted to account for the effect of
missing data by using a joint mixed-effects/survival model.
Our exploratory analysis suggests that the progressive devel-
opment of symptoms over time is associated with early
discontinuation of AI therapy. Most notably, increasing
scores in the musculoskeletal symptom cluster over time
wereassociatedwitha substantially increased risk fordiscontinu-
ing AI therapy early.
Despite the prevalence and negative effect of arthralgias
onHRQOL,the truemechanismfor thesesymptomsremains to
be fully understood. One hypothesis is based on the influence
of estrogen depletion. This is, in part, supported by findings
fromasurveystudy findingthat shorter interval since theonset
of menopause was associated with higher AI-associated
arthralgia burden, suggesting that these women might have
hada largerdecrease inabsoluteestrogen levels [21].Although
this is an interesting finding, our current data and prior work
from our group [22] have not observed an association with
absolute change inestrogenor estrogenmetabolites following
AI therapy and the onset of arthralgias. However, the current
study was underpowered for a definitive analysis, and larger
adequately powered studies are needed. More recently, an
inflammatory basis for arthralgia and other AI-associated
symptoms has been postulated [23]. Unfortunately, a recently
reported targeted anti-inflammatory therapy using omega-3
fatty acids showed no difference over placebo [24]. Overall,
these data, along with the current study, suggest that
successful interventions to improve overall HRQOL and
decrease early discontinuation will likely have to target
multiple domains.
If similar findings are validated in larger prospective studies,
this information could help inform studies of interventions to
improve tolerance of and adherence to therapy. For example,
inclusion of patients who develop treatment-emergent symp-
tomsearly in thecourseofAI therapymightenrich for amore “at
risk”population that ismore likely tobenefit fromtheadherence
intervention, thereby increasing thepower of the study.To date,
prospective trials, such as those evaluating patient educational
materials and/orsupportiveservices,havefailed todemonstrate
improvements in persistence rates of adjuvant endocrine
therapy [25–27]. The reason for the lack of improvement
observed in these trials couldbedue to the inclusionofa general
cohort of breast cancer patients, many of whom are unlikely to
discontinue treatment, rather than a prespecified group at
highest risk for nonpersistence.
Another issue that can result in decreased statistical power
to detect changes in PROmeasures is the enrollment of a cohort
of women with excellent baseline HRQOL and low levels of
depression and symptom burden. This is highlighted by the
consistent findings in trials of tamoxifen [28] and recent adjuvant
[29, 30] and neoadjuvant [31] trials of AI therapy that show little
changeinpsychologicaldistressduringthestudyperiod.Similarly,
theELPhstudyparticipantsasagrouphadnosignificantchangein
validated measures of depression or anxiety. As in the larger
studies discussedearlier,most patients in ELPhalsohad low rates
of depression and anxiety both at baseline and during therapy.
Patientswithahighpre-existingsymptomburdenmayhavemore
difficulty tolerating therapy compared with those without
symptoms, but they are generally not represented in large
numbers in clinical trials. Concomitant use of medications for
depression and anxiety during study participationmight affect
these measures over time. However, in the ELPh trial analysis,
because of limitations on available data regarding indications
for use of concomitant medications as well as low numbers of
patients who reported mood issues, analyses on concurrent
psychotropic medications use were not performed.
Despite the high incidence of early discontinuation due to
patient-reported symptom burden, analyses of the data from
the entire cohort and by drug are consistent with the available
bodyof literaturedescribingminimal change inPROsover time
in large randomized adjuvant AI trials [2–4, 29, 30, 32–34].
What then accounts for the high rate of nonadherence and
earlydiscontinuationobserved in clinical practice even though
theavailablestudiesoverwhelmingly suggestthatoverallPROs
are minimally affected? To answer this, it is important to
understand the difference between commonly used general
HRQOL versus symptom-focused PROs. Tools such as the
Functional Assessment of Cancer Therapy (FACT)-B and Short
Form-36 are psychometrically reliable and valid and measure a
variety ofdomains. Although these commonly usedHRQOL tools
areable tocapturedifferencesbetweenvariouspopulationsover
time (i.e., advanced cancer vs. minimal disease) their ability to
capture clinically important differences in trials involving well-
balanced populations that are comparing agents with similar
toxicityprofiles(i.e.,adjuvantendocrinetherapy)appears limited.
In contrast, symptom-specific measures, such as the select
itemsoftheendocrinesubscaleofFACT,are focusedona limited
Table 1. Baseline demographic characteristics (n5 490)
Characteristic Patients, n Mean value
Age 490 59 years
BMI 489 29 kg/m2
Drug assignment
Exemestane 243 50%
Letrozole 247 50%
Race
White 434 88%
Black/other 56 12%
Prior chemotherapy
Yes 222 45%
No 268 55%
Prior taxane
Yes 161 33%
No 329 67%
Prior tamoxifen
Yes 178 36%
No 310 63%
Missing 2 1%
Abbreviation: BMI, body mass index.
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set of adverse symptoms that might allow patients to respond
more precisely to symptom severity and allow investigators to
discern meaningful differences over time [35]. The large AI
adjuvant trials (such as the Arimidex, Tamoxifen Alone or in
Combination study; the Intergroup Exemestane Study; and
National Cancer Institute of Canada MA.17) exemplify this
phenomenon because they found nomeaningful difference in
overall HRQOLbetween treatmentarmswhileobserving some
distinct treatment-specific adverse endocrine symptoms.
CONCLUSION
In the prospective ELPh trial of adjuvant AI therapy for early-
stage breast cancer, worsening of multiple treatment-related
symptoms duringAI therapy predictedAI early discontinuation.
If these findings are confirmed in independent trials, early
detectionofchanges inPROmeasures could beused clinically
to target interventions in patients at high risk for early
discontinuation.
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